These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cbx3/HP1γ deficiency confers enhanced tumor-killing capacity on CD8 Sun M; Ha N; Pham DH; Frederick M; Sharma B; Naruse C; Asano M; Pipkin ME; George RE; Thai TH Sci Rep; 2017 Feb; 7():42888. PubMed ID: 28220815 [TBL] [Abstract][Full Text] [Related]
3. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models. Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930 [TBL] [Abstract][Full Text] [Related]
4. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Scharping NE; Rivadeneira DB; Menk AV; Vignali PDA; Ford BR; Rittenhouse NL; Peralta R; Wang Y; Wang Y; DePeaux K; Poholek AC; Delgoffe GM Nat Immunol; 2021 Feb; 22(2):205-215. PubMed ID: 33398183 [TBL] [Abstract][Full Text] [Related]
5. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells. Roberts DJ; Franklin NA; Kingeter LM; Yagita H; Tutt AL; Glennie MJ; Bullock TN J Immunother; 2010 Oct; 33(8):769-79. PubMed ID: 20842060 [TBL] [Abstract][Full Text] [Related]
6. DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells. Cueto FJ; Del Fresno C; Brandi P; Combes AJ; Hernández-García E; Sánchez-Paulete AR; Enamorado M; Bromley CP; Gomez MJ; Conde-Garrosa R; Mañes S; Zelenay S; Melero I; Iborra S; Krummel MF; Sancho D J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33980589 [TBL] [Abstract][Full Text] [Related]
7. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity. Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075 [TBL] [Abstract][Full Text] [Related]
8. G-CSF and G-CSFR Modulate CD4 and CD8 T Cell Responses to Promote Colon Tumor Growth and Are Potential Therapeutic Targets. Karagiannidis I; Jerman SJ; Jacenik D; Phinney BB; Yao R; Prossnitz ER; Beswick EJ Front Immunol; 2020; 11():1885. PubMed ID: 33042110 [TBL] [Abstract][Full Text] [Related]
9. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment. Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609 [TBL] [Abstract][Full Text] [Related]
10. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Kujawski M; Zhang C; Herrmann A; Reckamp K; Scuto A; Jensen M; Deng J; Forman S; Figlin R; Yu H Cancer Res; 2010 Dec; 70(23):9599-610. PubMed ID: 21118964 [TBL] [Abstract][Full Text] [Related]
11. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection. Dobrzanski MJ; Reome JB; Dutton RW J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679 [TBL] [Abstract][Full Text] [Related]
12. Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy. Gough M; Crittenden M; Thanarajasingam U; Sanchez-Perez L; Thompson J; Jevremovic D; Vile R J Immunol; 2005 May; 174(9):5766-73. PubMed ID: 15843579 [TBL] [Abstract][Full Text] [Related]
13. Combinatorial immunotherapy induces tumor-infiltrating CD8 Van Braeckel-Budimir N; Dolina JS; Wei J; Wang X; Chen SH; Santiago P; Tu G; Micci L; Al-Khami AA; Pfister S; Ram S; Sundar P; Thomas G; Long H; Yang W; Potluri S; Salek-Ardakani S J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903555 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models. Leone RD; Sun IM; Oh MH; Sun IH; Wen J; Englert J; Powell JD Cancer Immunol Immunother; 2018 Aug; 67(8):1271-1284. PubMed ID: 29923026 [TBL] [Abstract][Full Text] [Related]
19. IL-21 contributes to fatal inflammatory disease in the absence of Foxp3+ T regulatory cells. Vogelzang A; McGuire HM; Liu SM; Gloss B; Mercado K; Earls P; Dinger ME; Batten M; Sprent J; King C J Immunol; 2014 Feb; 192(4):1404-14. PubMed ID: 24446516 [TBL] [Abstract][Full Text] [Related]
20. Type 17 immunity promotes the exhaustion of CD8 Kim BS; Kuen DS; Koh CH; Kim HD; Chang SH; Kim S; Jeon YK; Park YJ; Choi G; Kim J; Kang KW; Kim HY; Kang SJ; Hwang S; Shin EC; Kang CY; Dong C; Chung Y J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083422 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]